Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Sales for Q2 FY12/24 were JPY316mn (-36.9% YoY), with an operating loss of JPY24mn, and sales progress at 34.1%.</li><li>Drug Discovery and Development segment recorded no sales, with an operating loss of JPY1.1bn, and increased R&D spending by 3.4% YoY.</li><li>Full-year forecast includes JPY925mn sales (+0.8% YoY) and JPY229mn operating profit (+1.8% YoY) for Drug Discovery Support segment.</li></ul>

Sales for Q2 FY12/24 were JPY316mn (-36.9% YoY), with an operating loss of JPY24mn, and sales progress at 34.1%.Drug Discovery and Development segment recorded no sales, with an operating loss of JPY1.1bn, and increased R&D spending by 3.4% YoY.Full-year forecast includes JPY925mn sales (+0.8% YoY) and JPY229mn operating profit (+1.8% YoY) for Drug Discovery Support segment.

Carna Biosciences (4572 JP): 1H FY12/24 flash update

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Thematic (Sector/Industry)

<p>The suggestion of government orchestration against <a href="https://www.smartkarma.com/entities/8979" target="_blank" data-smartkarma-citation="entities:8979:1">Ono</a>’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the Nikkei that the Japanese Health Ministry is considering setting rules on new drug usage during this fiscal year, starting with <a href="https://www.smartkarma.com/entities/8979" target="_blank" data-smartkarma-citation="entities:8979:1">Ono</a>’s Opdivo and <a href="https://www.smartkarma.com/entities/6091" target="_blank" data-smartkarma-citation="entities:6091">Astellas</a>’s Repatha. Patients may be limited to those who can see certain impact from the treatment, which in turn would mean the drug could only be prescribed at those institutions with the facilities to check…</p>

The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the Nikkei that the Japanese Health Ministry is considering setting rules on new drug usage during this fiscal year, starting with Ono’s Opdivo and Astellas’s Repatha. Patients may be limited to those who can see certain impact from the treatment, which in turn would mean the drug could only be prescribed at those institutions with the facilities to check…

Opdivo Singled Out in Government Rule Change

Japan

Carna Biosciences, Inc. is a biotechnology company. The Company specializes in intercellular signaling-based drug discovery, as well as as provide drug discovery services to pharmaceutical companies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Carna Biosciences (4572 JP)